SEC For																	
	FORM	4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					MT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940								P OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] DAVIS STEPHEN					2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ACAD]							ck all applica	able)	Reporting Person(s) to Issuer ble) 10% Owner jive title Other (specify			
(Last) (First) (Middle) C/O ACADIA PHARMACEUTICALS INC.					3. Date of Earliest Transaction (Month/Day/Year) 05/01/2023							below)	CEO		pecily		
12830 EL CAMINO REAL, SUITE 400					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) SAN DI	EGO C	92130									-	ed by Mor	•	rting Person One Report			
(City)	(5	itate)	(Zip)	ק ק ן	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Та	ble I - Non-De	rivati	ve Se	ecuritie	s Ac	quired, D	isposed	of, or Be	eneficially	/ Owned					
Date				ransactio hth/Day/		2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Dispo Code (Instr.		urities Acquired (A) or sed Of (D) (Instr. 3, 4 and		Beneficia Owned Fe	Form ly (D) or		Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amour	t (A) c (D)	Price	Reported Transacti (Instr. 3 a	tion(s)			Instr. 4)	
			Table II - Der (e.g					uired, Dis s, options,				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(0)			
Stock Options (Right to Buy)	\$21.75	05/01/2023		A		295,503		(1)	05/01/203	Common Stock	295,503	\$0.00	295,503		D		
Restricted Stock Units	(2)	05/01/2023		A		89,564		(3)	(3)	Common Stock	89,564	\$0.00	89,56	4	D		

Explanation of Responses:

1. 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

2. Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.

3. The restricted stock units vest in four equal annual installments beginning May 1, 2024.

Remarks:

/s/ Austin D. Kim, Attorney-in-Fact 05/03/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.